<DOC>
	<DOCNO>NCT01015248</DOCNO>
	<brief_summary>The aim study assess therapeutic activity safety combination Bendamustine Rituximab MALT lymphoma . Primary endpoint : - Event-free-survival ( EFS ) ( failure death cause ) patient . Secondary endpoint : - Complete partial remission rate patient - Response duration ( time relapse progression ) responder patient - Progression-free-survival ( PFS ) ( disease progression death lymphoma : patient - Overall survival patient - Acute long-term toxicity</brief_summary>
	<brief_title>Trial Bendamustine And Rituximab Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue ( MALT ) Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Histologically proven diagnosis CD20positive marginal zone Bcell lymphoma MALT type arisen extranodal site ( WHO classification ) 2 . Any stage ( Ann Arbor IIV ) 3 . The novo disease en extranodal site . For primary gastric cutaneous lymphoma , local/specific previous treatment accept , follow criterion : 1 . Cutaneous lymphoma : recurrent lymphoma local therapy 2 . Gastric lymphoma : b1 . H. pylorinegative case , either de novo ( non pretreated ) relapse follow local therapy ( i.e. , surgery , radiotherapy antibiotic ) . b2 . H. pyloripositive case diagnosis , fail antibiotic therapy , include patient : clinical ( endoscopic ) histological evidence disease progression time post H. pylorus eradication ; stable disease persistent lymphoma 1 year post H. pylorus eradication ; relapse ( without H. pylorus reinfection ) , remission ; patient fail either first line antibiotic local treatment ( surgery radiotherapy ) 4 . No evidence histologic transformation high grade lymphoma 5 . Measurable evaluable disease 6 . Age &gt; 18 &lt; 85 7 . ECOG performance status 02 8 . Life expectancy least 1 year 9 . Written informed consent give accord national/local regulation 1 . Prior chemotherapy prior immunotherapy antiCD20 monoclonal antibody 2 . Prior radiotherapy last 6 week 3 . Corticosteroids last 28 day , unless prednisone chronically administer dose &lt; 20 mg/day indication lymphoma lymphomarelated symptom 4 . Major impairment renal function ( serum creatinine &gt; 2,5 x upper normal ) liver function ( ASAT/ALAT &lt; 2,5 x upper normal , total bilirubin &lt; 2,5x upper normal ) , unless due lymphoma involvement . 5 . Impairment bone marrow function ( WBC &lt; 3.0x109/L , ANC &lt; 1.5x109/L , PLT &lt; 100x109/L ) , unless due lymphoma involvement 6 . Evidence clinically significant cardiac , neurological metabolic disease , unless due lymphoma involvement 7 . Evidence symptomatic central nervous system ( CNS ) disease 8 . Active HBV and/or HCV infection 9 . Known HIV infection 10 . Prior diagnosis neoplasm within 5 year , except cervical intraepithelial neoplasia type 1 ( CIN1 ) localize nonmelanomatous skin cancer 11 . Any psychiatric disease potentially hamper compliance study protocol followup schedule 12 . Potential attend regular visit hospital , outpatient regimen 13 . Hypersensibility compound study medication . 14 . Non appropriate contraceptive method woman childbearing potential men 15 . Treatment drug research within 30 day previous start study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>CD 20 positive</keyword>
</DOC>